Advertisement

Topics

Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?

11:40 EDT 19 Oct 2016 | STAT

Pfizer's biosimilar for a J&J rheumatoid arthritis treatment sparked concerns among J&J investors. But an analyst said such worries may be uncalled for.

Original Article: Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?

NEXT ARTICLE

More From BioPortfolio on "Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...